The current research on evaluating the progress of liver fibrosis by serum markers
-
摘要: 肝纤维化是各种慢性肝病重要的病理特征,也是进一步向肝硬化发展的必经阶段,早期诊断和治疗对阻止肝纤维化发展为肝硬化具有重要意义。肝活检仍是诊断肝纤维化的金标准,但具有创性,不易动态观察,临床应用受到限制,因此需寻求理想的无创诊断方法。在过去的十年中,肝纤维化进展相关的血清标志物研究取得了很大的进展,为肝纤维化的无创诊断带来了新希望。Abstract: Liver fibrosis is not only a significant feature of various liver diseases, but also the inevitable stage to liver cirrhosis.In order to prevent the progress to cirrhosis, it is important to diagnose and treat liver fibrosis early.Liver biopsy is still the gold standard for the diagnosis of liver fibrosis.But because its invasive trait and limited repeatability, its application is restricted.Thus it is necessary to seek ideal non-invasive method.Last decade's breakthroughs of serum markers brought new hope to the diagnosis.
-
Key words:
- liver cirrhosis /
- biological markers
-
[1]Bonis PA, Friedman SL, Kaplan MM.Is liver fibrosis reversible?[J].N Engl J Med, 2001, 344 (6) :452-454. [2]Friedman SL.Mechanisms of hepatic fibrogenesis[J].Gastroenter-ology, 2008, 134 (6) :1655-1669. [3]Novo E, Parola M.Redox mechanisms in hepatic chronic wound healingand fibrogenesis[J].Fibrogenesis Tissue Repair, 2008, 1 (1) :5. [4]Borkham-Kamphorst E, Claudia RC, van Roeyen CR, et al.Pro-fibrogenic potential of PDGF-D in liver fibrosis[J].J Hepatol, 2007, 46 (6) :1064-1074. [5]Zhou K, Gao CF, Zhao YP, et al.Simpler score of routine labora-tory tests predicts liver fibrosis in patients with chronic hepatitis B[J].J Gastroenterol Hepatol, 2010, 25 (9) :1569-1577. [6]Gressner OA, Weiskirchen R, Gressner AM.Biomarkers of liver fi-brosis:clinical translation of molecular pathogenesis or based on liv-er-dependent malfunction tests[J].Clin Chim Acta, 2007, 381 (2) :107-113. [7]Giannini E, Caglieris S, Ceppa P, et al.Serum pro-collagen IIIpeptide levels are related to lobular necrosis in untreated patientswith chronic hepatitis C[J].Eur Gastroenterol Hepatol, 2001, 13 (2) :137-141. [8]Degott C, Zafrani ES, Callard P, et al.Histopathological study of pri-mary biliary cirrhosis and the effect of ursodeoxycholic acid treatment onhistology progression[J].Hepatology, 1999, 29 (4) :1007-1012. [9]George DK, Ramm GA, Walker NI, et al.Elevated serum type IVcollagen:a sensitive indicator of the presence of cirrhosis in haemo-chromaosis[J].J Hepatol, 1999, 31 (1) :47-52 [10]Murawaki Y, Ikuta Y, Okamoto K, et al.Diagnostic value of serummarkers of connective tissue turnover for predicting histological stag-ing and grading in patients with chronic hepatitis C[J].J Gastroen-terol, 2001, 36 (6) :399-406. [11]Saitou Y, Shiraki K, Yamanaka Y, et al.Noninvasive estimation ofliver fibrosis and response to interferon therapy by a serum fibrogen-esis marker, YKL-40, in patients with HCV-associated liver dis-ease[J].World J Gastroenterol, 2005, 11 (4) :476-481. [12]Johansen JS.Studies on serumYKL-40 as a biomarker in diseaseswith inflammation, tissue remodelling, fibroses and cancer[J].DanMed Bull, 2006, 53 (2) :172-209. [13] Walsh KM, Timms P, Campbell S, et al.Plasma levels of matrixmetalloproteinase-2 (MMP-2) and tissue inhibitors of metallo-proteinases-1 and-2 (TIMP-1 and TIMP-2) as noninvasivemarkers of liver disease in chronic hepatitis C:comparison usingROC analysis[J].Dig Dis Sci, 1999, 44 (3) :624-630. [14]Quan TE, Cowper S, Wu SP, et al.Circulating fibrocytes:collagen-secreting cells of the peripheral blood[J].Int J Biochem Bio, 2004, 36 (4) :598-606. [15]Gressner OA, Gressner AM.Connective tissue growth factor:a fi-brogenic master switch in fibrotic liver diseases[J].Liver Int, 2008, 28 (8) :1065-1079. [16]Tacke F, Gabele E, Bataille F, et al.Bone morphogenetic protein7 is elevated in patients with chronic liver disease and exerts fibro-genic effects on human hepatic stellate cells[J].Dig Dis Sci, 2007, 52 (12) :3404-3415. [17]Camps J, Marsillach J, Joven J.Measurement of serum paraoxonase-1 activity as a potential biomarker for chronic liver impairment[J].Clin Chim Acta, 2007, 386 (1-2) :114-115. [18]Kuhn J, Gressner OA, Gotting C, et al.Increased serum xylosyl-transferase activity in patients with liver fibrosis[J].Clin Chim Ac-ta, 2009, 409 (1-2) :123-126. [19]Schttler M, Müller S, Schn S, et al.Serum xylosyltransferase Iactivity, the new biochemical fibrosis marker, is not affected by renalinsufficiency[J].Clin Biochem, 2005, 38 (5) :486-488. [20]Poon TC, Hui AY, Chan HL, et al.Prediction of l iver fibrosis andcirrhosis in chronic hepatitis B infection by serum proteomic F Inger-printing:a pilot study[J].Clin Chem, 2005, 51 (2) :328-335. [21]Callewaert N, VLierberghe HV, Hecke AV, et al.Noninvasive diag-nosis of liver cirrhosis using DNA sequencer-based total serum pro-tein glycomics[J].Nat Med, 2004, 10 (4) :429-434. [22]Zeng MD, Lu LG, Mao YM, et al.Prediction of significant Fibrosisin HBeAg-Positive Patients with Chronic Hepatitis B by a Noninva-sive Modelogy[J].Hepatology, 2005, 42 (6) :1437-1445. [23]Franzini M, Corti A, Fornaciari I, et al.Cultured human cells re-lease soluble gamma-glutamyltransferase complexes correspondingto the plasma b-GGT[J].Biomarkers, 2009, 14 (7) :486-492. [24]Shaheen AA, Myers RP.Diagnostic accuracy of the aspartate amin-otransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis:a systematic review[J].Hepatology, 2007, 46 (3) :912-921. [25]Jacqueminet S, Lebray P, Morra R, et al.Screening for liver fibro-sis by using a noninvasive biomarker in patients with diabetes[J].Clin Gastroenterol Hepatol, 2008, 6 (7) :828-831. [26]Poynard T, Ngo Y, Marcellin P, et al.Impact of adefovir dipivoxilon liver fibrosis and activity assessed with biochemical markers (Fi-broTest-ActiTest) in patients infected by hepatitis B virus[J].JViral Hepat, 2009, 16 (3) :203-213. [27]Castera L.Transient elastography and other noninvasive tests to as-sess hepatic fibrosis in patients with viral hepatitis[J].J Viral Hep-at, 2009, 16 (5) :300-314.
本文二维码
计量
- 文章访问数: 3360
- HTML全文浏览量: 15
- PDF下载量: 738
- 被引次数: 0